Johnson & Johnson (JNJ) Q2 2026 Financial Results Summary
· Stocks · QuoteReporter
Johnson & Johnson (JNJ) Q2 2026: Revenue Growth and Raised Guidance — Positive Outlook
Johnson & Johnson (NYSE: JNJ) reported its Q2 2026 results, showcasing a revenue growth of $25.3 billion, which represents an increase of $1.6 billion or +6.6% compared to Q2 2025's revenue of $23.7 billion. This performance indicates a solid quarter for shareholders, as the company not only achieved revenue growth but also raised its full-year guidance.
Key Financial Metrics:
- Reported Sales: $25,310 million in Q2 2026 vs. $23,743 million in Q2 2025 (+6.6% YoY)
- Net Earnings: $5,534 million in Q2 2026 vs. $5,537 million in Q2 2025 (-0.1% YoY)
- EPS (diluted): $2.27 in Q2 2026 vs. $2.29 in Q2 2025 (-0.9% YoY)
- Adjusted Net Earnings: $7,081 million in Q2 2026 vs. $6,699 million in Q2 2025 (+5.7% YoY)
- Adjusted EPS: $2.90 in Q2 2026 vs. $2.77 in Q2 2025 (+4.7% YoY)
- Free Cash Flow: ~$8,700 million in Q2 2026 vs. $6,214 million in Q2 2025
Analyst Opinion:
This quarter can be viewed positively by shareholders. The revenue growth of $1.6 billion reflects strong operational performance, and the increase in adjusted EPS by $0.13 to $2.90 demonstrates effective cost management and profitability. Although net earnings and diluted EPS saw slight declines, the overall growth in sales and adjusted earnings suggests that the company is on a solid trajectory. Furthermore, the raised guidance for 2026 indicates confidence in sustained performance moving forward.
Guidance Changes:
- 2026 Reported Sales Guidance: Increased to $101.1 billion (midpoint), reflecting a growth of 7.3% at the midpoint.
- Adjusted EPS Guidance: Increased by $0.13 to $11.68 (midpoint), representing an 8.2% growth at the midpoint.
- Adjusted Operational EPS Guidance: Increased by $0.18 to $11.58 (midpoint), indicating a 7.3% growth at the midpoint.
Regional and Segment Performance:
- U.S. Sales: $14,533 million in Q2 2026 vs. $13,544 million in Q2 2025 (+7.3% YoY)
- International Sales: $10,777 million in Q2 2026 vs. $10,199 million in Q2 2025 (+5.7% YoY)
- Innovative Medicine Segment: $16,384 million in Q2 2026 vs. $15,202 million in Q2 2025 (+7.8% YoY)
- MedTech Segment: $8,926 million in Q2 2026 vs. $8,541 million in Q2 2025 (+4.5% YoY)
The Innovative Medicine segment continues to drive growth, particularly with products like DARZALEX and TREMFYA. The MedTech segment also showed resilience, although growth was slightly lower compared to the Innovative Medicine segment.
Forward Catalysts:
Investors should watch for continued innovation and product approvals, as Johnson & Johnson has several significant advancements in its pipeline. The recent approvals of TREMFYA and CAPLYTA, along with ongoing clinical trials for new therapies, could further enhance the company's growth trajectory. Additionally, the company's commitment to expanding its oncology pipeline through acquisitions, such as Firefly Bio, will be crucial for long-term growth.
In conclusion, Johnson & Johnson's Q2 2026 results reflect a robust performance with significant revenue growth and an optimistic outlook for the remainder of the year. The raised guidance and strong operational metrics position the company favorably in the healthcare sector, making it an attractive option for investors looking for stability and growth.
Here are the extracted tables from the press release:
Condensed Consolidated Statements of Earnings
(Amounts in Millions)
Note: The amounts are in thousands/millions.
| Q2 2026 | Q2 2025 | % Change | |
|---|---|---|---|
| Reported Sales | $25,310 | $23,743 | 6.6% |
| Net Earnings | $5,534 | $5,537 | -0.1% |
| EPS (diluted) | $2.27 | $2.29 | -0.9% |
| Operational Sales | 5.6% | ||
| Adjusted Operational Sales | 5.7% | ||
| Adjusted Net Earnings | $7,081 | $6,699 | 5.7% |
| Adjusted EPS (diluted) | $2.90 | $2.77 | 4.7% |
| Free Cash Flow | ~$8,700 | $6,214 |
Condensed Consolidated Balance Sheets
(Amounts in Millions)
Note: The Balance Sheet data is incomplete as specific values were not included in the provided press release data.
| Q2 2026 | Q2 2025 | |
|---|---|---|
| Assets | ||
| Current Assets | ||
| Cash and Cash Equivalents | ||
| Accounts Receivable | ||
| Inventories | ||
| Other Current Assets | ||
| Total Current Assets | ||
| Non-current Assets | ||
| Property, Plant and Equipment, net | ||
| Long-term Financing Receivables | ||
| Intangible Assets | ||
| Other Non-current Assets | ||
| Total Non-current Assets | ||
| Total Assets | ||
| Liabilities | ||
| Current Liabilities | ||
| Accounts Payable | ||
| Short-term Debt | ||
| Other Current Liabilities | ||
| Total Current Liabilities | ||
| Non-current Liabilities | ||
| Long-term Debt | ||
| Other Non-current Liabilities | ||
| Total Non-current Liabilities | ||
| Total Liabilities | ||
| Equity | ||
| Common Stock and Additional Paid-in Capital | ||
| Retained Earnings | ||
| Accumulated Other Comprehensive Income | ||
| Total Equity | ||
| Total Liabilities and Equity |
Disclaimer
The content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments carry risk and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from the use of this information.